Mikhail Blagosklonny’s Contribution In Cancer And Aging Research

Mikhail Blagosklonny is a cancer and aging scientist. He works at Roswell Park Cancer Institute, Buffalo, New York as an oncology professor. Mikhail is an alumnus of the First Pavlov State Medical University of St. Petersburg where he earned his M.D in internal medicine and a PhD in experimental medicine and cardiology.

According to Impact Journals, Mikhail Blagosklonny joined New York Medical College in 2002 as an associate professor of medicine and later took up a role of senior scientist at Ordway Research Institute Albany, NY. He worked here until 2009 when he joined Roswell Park Cancer Institute.

Research Gate reveals that Mikhail Blagosklonny has researched on a wide range of topics in the field including molecular and cellular biology and clinical investigations, narrowing down to oncogenes and tumor suppressors, cell cycle, signal transduction, apoptosis, mitosis, resistance of drugs for selective protection of normal cells and anticancer therapeutics focusing on basic science in new anticancer strategies.

Under this aging research, Mikhail Blagosklonny formulated a hypothesis to study the possible role of TOR signaling in cancer and aging.

The clinical significance of this research showed that suppressed TOR activity extends life span in S. cerevisiae, D. melanogaster and C. elegans. Rapamycin, which inhibits mTOR was found to increase mice’s lifespan. Studies have indicated that some dietary regimes like methionine restriction and caloric restriction decreases mTOR activity, resulting into lifespan extension.

There have also been suggestions that aging may increase mTOR signaling in certain tissues like the adipose tissue. In cancer, mTOR activity was revealed to be deregulated in most types of cancer while over-activation of mTOR signaling enhances the development of tumors.

Mikhail Blagosklonny is the founder and editor-in-chief of Cell Cycle, Aging and Oncotarget. He is an active member of the editorial board of Cell Death & Differentiation.

He is also an associate editor for Cancer Biology & Therapy. Mikhail works for Autophagy, The American Journal of Pathology, PLOS ONE and Cancer Research as an associate editor.